Here are the 10-K annual reports from ADC Therapeutics SA (ADCT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ADCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADCT filings page.
ADC Therapeutics SA is a commercial-stage oncology company focused on antibody drug conjugates, led by its CD19-directed therapy ZYNLONTA for relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) after at least two prior treatments. ZYNLONTA has accelerated or conditional approvals in the United States, European Union, China and Canada and is being expanded through the global Phase 3 LOTIS‑5 trial in second‑line and later DLBCL and the LOTIS‑7 Phase 1b combination trial with glofitamab and other agents.
The company is also pursuing investigator‑initiated studies in marginal zone and follicular lymphomas, and has completed IND‑enabling work on PSMA‑targeting ADC ADCT‑241 for prostate cancer, which it aims to partner. Commercially, ADC Therapeutics sells ZYNLONTA directly in the U.S. and relies on regional partners Overland, Mitsubishi Tanabe (TPC) and Sobi elsewhere, while paying a capped royalty to HealthCare Royalty under a financing agreement and servicing a term loan with Oaktree and Owl Rock. Common shares outstanding were 127,044,356 as of March 2, 2026.